1-2 of 2
Emil Spasov, MD
Close
Sort by
Journal Articles

Therapeutic Results in Patients with Hodgkin's Lymphoma Treated with Brentuximab Vedotin — Bulgarian Experience

Veselina S Goranova Marinova, MD PhD, Kalina Ignatova, MD, Penka Ganeva, MD, Emil Spasov, MD PhD, Ilina Micheva, MD PhD, Atanas Radinov, MD, Raya Petrova, MD, Gergana Tzvetkova, MD, Eugueni Hadzhiev, MD PhD, Stefan E Goranov, MD PhD DMSc, Liana Gercheva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5193.
https://doi.org/10.1182/blood.V130.Suppl_1.5193.5193
Published: 2017
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007